BEIJING, Oct. 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that it has been selected as a nominee for the 7th Annual Scrip Awards in the category of "Best Company in an Emerging Market." The winner will be announced at the awards ceremony on November 3, 2011 at the Grosvenor House hotel in London.
According to Scrip, the Scrip Awards recognize outstanding performance across a range of business activities and provide the biopharmaceutical industry with the opportunity to acknowledge and applaud its highest achievers in all phases of the value chain. The awards can recognize both corporate and individual achievement.
The awards are open to any company or individual in the biopharmaceutical industry. A panel of 16 highly respected and independent luminaries from the global biopharmaceutical industry first votes a shortlist of nominees and then chooses the winners for each category. Please visit http://www.scripintelligence.com/awards/ for more information about the awards. Of the six companies selected for the shortlist in the category of "Best Company in an Emerging Market," China Biologic was the only Chinese company to be included.
Mr. Chao Ming Zhao, the Company's Chief Executive Officer, said, "We are very pleased to be a candidate for one of our global industry's highest awards. We see our nomination as an important international recognition for our work and success over the past several years.
"We believe this nomination reflects the outstanding quality of our existing products, our new product development process and results, and our growth as one of the leading plasma-based biopharmaceutical companies in China."
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. Its plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. China Biologic sells its products to hospitals and other healthcare facilities in China. Please visit its website at www.chinabiologic.com for additional information.
Safe harbor statement
This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Telephone: +86 53 8620 2206
|SOURCE China Biologic Products, Inc.|
Copyright©2010 PR Newswire.
All rights reserved